Product image of Letrozol Phace (Letrozole) supplied by GNH India

Letrozol Phace

Active Ingredient:
Letrozole
Origin:
EU

Letrozol Phace (Letrozole)

Letrozole, the active ingredient in Letrozol Phace, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed to lower estrogen production and is indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women, helping to slow tumor growth.

GNH India supplies Letrozol Phace as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution, with reliable logistics and support for import documentation.

Manufacturer / TM Owner

Pharmacenter Europe Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Letrozole is an aromatase inhibitor used primarily in the estrogen‑dependent breast cancer treatment pathway, addressing disease at various stages.

  • Early‑stage hormone receptor‑positive breast cancer (adjuvant): Reduces risk of disease recurrence after surgery.
  • Metastatic hormone receptor‑positive breast cancer: Delays disease progression in postmenopausal patients.
  • Neoadjuvant therapy for locally advanced hormone receptor‑positive breast cancer: Shrinks tumor size before surgery.

How It Works

  • Letrozole reversibly binds to the heme group of the aromatase enzyme (CYP19A1), inhibiting its catalytic activity. By blocking aromatase, the conversion of adrenal and peripheral androgens (androstenedione and testosterone) to estrone and estradiol is markedly reduced, leading to lower circulating estrogen levels. In postmenopausal women, this estrogen depletion deprives estrogen‑dependent tumor cells of a growth stimulus, thereby slowing or halting tumor proliferation.

Side Effects

Letrozole may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

  • Hot flashes: sudden feeling of warmth and sweating.
  • Joint and muscle pain: arthralgia and myalgia.
  • Fatigue: persistent tiredness.
  • Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects

  • Osteoporosis or bone fracture: decreased bone mineral density leading to fractures.
  • Severe liver injury: marked elevation of transaminases or hepatitis.
  • Cardiovascular events: thromboembolic disorders or myocardial infarction.

Precautions & Warnings

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure safe use.

  • Assess bone health: baseline DEXA scan recommended for osteoporosis risk.
  • Monitor liver function: periodic liver enzyme tests advised.
  • Evaluate cardiovascular risk: consider history of thromboembolism.
  • Review concomitant medications: avoid drugs that strongly induce CYP3A4.
  • Pregnancy and lactation: contraindicated; ensure effective contraception in women of childbearing potential.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Avoid Interactions

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce letrozole plasma levels.
  • Anticoagulants (e.g., warfarin): increased risk of bleeding; monitor INR closely.

Moderate Interactions (Monitor Closely)

  • CYP2C19 inhibitors (e.g., fluconazole): may increase letrozole exposure.
  • Hormone replacement therapy: may counteract estrogen‑lowering effect.
  • Selective serotonin reuptake inhibitors (e.g., fluoxetine): potential for altered metabolism.

Frequently Asked Questions

Letrozol Phace contains letrozole, an aromatase inhibitor indicated for the treatment of hormone receptor‑positive breast cancer in postmenopausal women. It is used in adjuvant, neoadjuvant, and metastatic settings to lower estrogen levels that can stimulate tumor growth.

Letrozole blocks the aromatase enzyme (CYP19A1), preventing the conversion of androgens into estrogens. This results in markedly reduced circulating estrogen, depriving estrogen‑dependent cancer cells of a key growth signal and thereby inhibiting tumor proliferation.

The prescribed dose of Letrozol Phace is determined by the treating physician based on the patient’s clinical condition, renal and hepatic function, and treatment goals. Dosage adjustments are made only under medical supervision.

Letrozole is contraindicated in pregnancy and breastfeeding because it can interfere with fetal and neonatal estrogen production. Women of childbearing potential must use effective contraception while receiving the medication, and it should not be used during pregnancy or lactation.

To order Letrozol Phace, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Letrozole, anastrozole, and exemestane are the three main aromatase inhibitors used in breast cancer. Letrozole is often chosen for its potent and sustained estrogen suppression, while anastrozole has a similar efficacy profile with a slightly different side‑effect spectrum. Choice of agent depends on individual patient factors, tolerability, and physician preference.

Letrozol Phace should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Letrozol Phace is taken orally as a tablet. Patients should swallow the tablet whole with a glass of water, preferably at the same time each day, and may take it with or without food as directed by their healthcare provider.

Serious risks include significant bone loss leading to osteoporosis or fractures, severe liver injury, and cardiovascular events such as thromboembolism or myocardial infarction. Patients should be monitored regularly for bone density, liver function, and cardiovascular health while on therapy.

Letrozol Phace should not be used in premenopausal women, pregnant or breastfeeding individuals, patients with severe hepatic impairment, or those with known hypersensitivity to letrozole or any excipients. Caution is also advised in patients with a history of osteoporosis or cardiovascular disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Letrozole

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT